When the cases showing positive expression of both myosin IIA and vimentin were evaluated, we recognised a 5-year-survival rate benefit of approximately 19% in patients who had undergone PAC with uracil–tegafur, but there was no statistically significant difference in this respect between patients who had and who had not received PAC. The gene discussed is VIM; the disease is gonorrhea.